Kiniksa Pharmaceuticals Ltd reports results for the quarter ended in December - Earnings Summary

Kiniksa Pharmaceuticals International

22/02/2022 14:27

* Kiniksa Pharmaceuticals Ltd  KNSA.OQ  reported a quarterly
adjusted loss of 53 cents​​ per share for the quarter ended in
December. The mean expectation of four analysts for the quarter
was for a loss of 42 cents per share.
    * Revenue was $18.75 million​;  analysts expected $20.72
million. 
    * Kiniksa Pharmaceuticals Ltd's reported EPS for the quarter
was a
loss of 53 cents​.
    * The mean earnings estimate of analysts had risen by
about 1.8%
in the last three months.​ 
    * In the last 30 days there have been no negative revisions
of
earnings estimates 
    * Kiniksa Pharmaceuticals Ltd shares had fallen by 8.9% this
quarter.
    * The company reported a quarterly loss of $36.33 million.
    * Wall Street's median 12-month price target for Kiniksa
Pharmaceuticals Ltd is $28.00 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 5 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 

This summary was machine generated February 22 at 02:27 p.m.
 ​All figures in US dollars unless otherwise stated